Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1A SAD/MAD of Inhaled Seralutinib (GB002) in Healthy Adults
NCT03473236Phase 1Completed
- Sponsor
- Gossamer Bio
- Start
- Sep 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of seralutinib in pulmonary arterial hypertension (PAH) (8 cohorts), sponsored by Gossamer Bio. Primary endpoints: Treatment-Emergent Adverse Events at 35 days, Vital Sign Findings Reported as TEAEs at 35 days and 9 more. Started Sep 2017; status: completed.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03473236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473236.